Navigation

Lymphoma (follicular non-Hodgkin's) - rituximab

Rituximab for the maintenance treatment of follicular non-Hodgkin's lymphoma following response to first-line chemotherapy

Status: History
Expected date of issue: July 2011
Referral date: March 2009
Process: STA
Notes:

Cancer reform strategy Batch 5

Topic area:
  • Cancer
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Panagiota Vrouchou
Communications manager: Katie Williamson
Project manager: Jeremy Powell
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 10 August 2010
1st appraisal committee meeting: 04 November 2010
2nd appraisal committee meeting 03 February 2011
3rd appraisal committee meeting: 05 April 2011
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Roche (rituximab)

Patient/carer groups

  • Leukaemia CARE
  • Lymphoma Association

Professional groups

  • British Society for Haematology
  • Cancer Networks Pharmacists Forum
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians, Medical Oncology Joint Special Committee
  • United Kingdom Oncology Nursing Society

Others

  • Department of Health
  • NHS Camden
  • Welsh Assembly Government

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Medicines and Healthcare products Regulatory Agency
  • NHS Quality Improvement Scotland

Comparator manufacturer(s)

  • Bayer (Ibritumomab tiuxetan) - did not submit confidentiality agreement

Relevant research groups

  • Leukaemia & Lymphoma Research

Evidence review group

  • National Institute for Health Research Health Technology Assessment Programme
  • Liverpool Reviews & Implementation Group, University of Liverpool (LRiG)

Associated guideline groups

  • None

Associated public health groups

  • None

Top


 

Project history

Date Update
11 November 2009 Following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.  Therefore, we now anticipate that the appraisal will begin during late February 2010. The deadline for submissions is expected in approximately early May 2010.
Top


 

Key documents

This page was last updated: 22 June 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.